Resistant Arterial Hypertension Cohort Study
RAHyCo
Interventional Prospective Cohort Study, Multi-center With Nested Case-control Studies (Family-based and Non-family Based) on Individuals With Resistant Arterial Hypertension.
3 other identifiers
observational
74
1 country
3
Brief Summary
The purpose of this study is to investigate the epidemiology of resistant hypertension, evaluate the efficacy and feasibility of a standardized drug treatment regimen (including the randomization of two doses of the diuretic used - chlorthalidone), study two interventions in the group of patients that is non-compliant, and study environmental and genetic variables of individuals with resistant hypertension in a family design.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2011
Longer than P75 for all trials
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 8, 2010
CompletedFirst Posted
Study publicly available on registry
March 9, 2010
CompletedStudy Start
First participant enrolled
April 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2017
CompletedOctober 30, 2018
October 1, 2018
6.1 years
March 8, 2010
October 26, 2018
Conditions
Outcome Measures
Primary Outcomes (1)
blood pressure control
at 12 weeks after initiation of standard treatment
Secondary Outcomes (1)
cardiovascular morbidity and mortality
5 years
Study Arms (3)
chlorthalidone
motivational invervention
motivational interview(s) vs. repeated calls vs. no particular intervention
standardized anti-hypertensive treatment
Interventions
motivational interview(s) vs. repeated calls vs. no particular intervention
olmesartan, amlodipine, chlorthalidone, +- spironolactone
Eligibility Criteria
patients addressed to a speciality consultation at Geneva University Hospital
You may qualify if:
- informed consent
- years or more, both sexes are included
- women at reproductive age: consenting to use oral contraception
You may not qualify if:
- patients mentally impaired or unable to give informed consent
- patients speaking only a foreign language other than French, German, or English
- patients living far away, making the study visits not practical
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
Geneva University Hospitals
Geneva, Switzerland
Lausanne University Hospital, CHUV
Lausanne, Switzerland
Kantonsspital Luzern
Lucerne, Switzerland
Biospecimen
serum, DNA, urine
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Antoinette PECHERE, MD
Geneva University Hospitals, Switzerland
- PRINCIPAL INVESTIGATOR
Georg B EHRET, MD
Geneva University Hospitals, Switzerland
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- intern
Study Record Dates
First Submitted
March 8, 2010
First Posted
March 9, 2010
Study Start
April 1, 2011
Primary Completion
May 1, 2017
Study Completion
May 1, 2017
Last Updated
October 30, 2018
Record last verified: 2018-10